In clinical research, the expression of carnitine palmitoyltransferase 2 (CPT2), which is responsible for converting acylcarnitine back to acyl-CoA, is reduced in human steatohepatitic HCC (SH-HCC) (Figure 2). This evidence concerns the gene CPT2 and hepatocellular carcinoma.